Pacira BioSciences(PCRX) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Zhitong FinanceMar 18 03:00 ET
New York Manufacturing Hits Low, Inflation Fears Rise
InvestingMar 17 08:50 ET
Shareholder Nominates Candidates for Pacira Board To Boost Returns
WSJMar 14 16:39 ET
Express News | Pacira Biosciences Confirms Receipt of Director Nominations From Doma Perpetual
ReutersMar 14 16:05 ET
Press Release: Pacira BioSciences Confirms Receipt of Director Nominations From DOMA Perpetual
Dow JonesMar 14 16:05 ET
Express News | Doma Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira Biosciences
ReutersMar 14 08:25 ET

Comments

Value investorr

Aug 24, 2024 00:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

4

Value investorr

Aug 19, 2024 23:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

2

Mr Long Term

Aug 14, 2024 06:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

12

2

Value investorr

Aug 12, 2024 22:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...

5

1

Shroomie

Aug 10, 2024 04:03

pew pew.. in and out in 30 seconds

$Pacira BioSciences (PCRX.US)$

Share Your Profit/Loss

2

10

PCRX Pacira BioSciences

Trade Overview

Capital Trend

News

Comments

Market Insights